Chong Kun Dang Pharmaceutical Corp.

A185750

KR7185750007

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 21/05/2024 BST			5-day change	1st Jan Change
100,500 ^KRW	-1.08%		-3.55%	-23.22%

04-25	Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on January 23, 2024.	CI
01-23	Chong Kun Dang Pharmaceutical Corp. announces an Equity Buyback for KRW 15,000 million worth of its shares.	CI

Chong Kun Dang Pharmaceutical Corp. authorizes a Buyback Plan.

October 12, 2022

The Board of Directors of Chong Kun Dang Pharmaceutical Corp. has authorized a buyback plan on October 13, 2022.

Latest news about Chong Kun Dang Pharmaceutical Corp.

Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on January 23, 2024.	04-25	CI
Chong Kun Dang Pharmaceutical Corp. announces an Equity Buyback for KRW 15,000 million worth of its shares.	01-23	CI
Chong Kun Dang Pharmaceutical Corp. authorizes a Buyback Plan.	01-22	CI
Chong Kun Dang Pharmaceutical Inks Largest-Ever Technology Transfer Agreement with Novartis	11-08	MT
Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on October 13, 2022.	16/10/23	CI
Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on October 13, 2022.	16/10/23	CI
Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on October 13, 2022.	16/10/23	CI
Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback announced on October 13, 2022, has expired with 62,127 shares, representing 0.51% for KRW 4,856.39 million.	15/10/23	CI
Chong Kun Dang Pharmaceutical Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on February 10, 2022.	14/02/23	CI
Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on February 10, 2022.	14/02/23	CI
Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on February 10, 2022.	14/02/23	CI
Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on February 10, 2022.	14/02/23	CI
Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback announced on February 10, 2022, has expired with 109,064 shares, representing 0.89% for KRW 9,895.01 million.	09/02/23	CI
Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on October 13, 2022.	18/01/23	CI
Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on October 15, 2020.	19/10/22	CI
Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on October 15, 2020.	19/10/22	CI
Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on October 15, 2020.	19/10/22	CI
Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on October 15, 2020.	19/10/22	CI
Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on October 15, 2020.	19/10/22	CI
Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback announced on October 15, 2020, has expired with 160,533 shares, representing 1.35% for KRW 19,650.63 million.	14/10/22	CI
Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on October 15, 2020.	13/10/22	CI
Chong Kun Dang Pharmaceutical Corp. announces an Equity Buyback for KRW 5,000 million worth of its shares.	13/10/22	CI
Chong Kun Dang Pharmaceutical Corp. authorizes a Buyback Plan.	12/10/22	CI
Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on February 10, 2022.	13/05/22	CI

Chart Chong Kun Dang Pharmaceutical Corp.

Duration

Period

Chart Chong Kun Dang Pharmaceutical Corp.

More charts

Chong Kun Dang Pharmaceutical Corp is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is mainly involved in the production and sale of prescription drugs such as antidiabetic treatments, cerebrovascular disease treatments, hypertension treatments and hyperlipidemia therapies. In addition, the Company provides over the counter (OTC) drugs including penzal, prefermine and modcol; quasi-drugs including insecticides and hair dyes; and health functional food. The company sells products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Chong Kun Dang Pharmaceutical Corp.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
CHONG KUN DANG PHARMACEUTICAL CORP.	-23.22%	950M
OTSUKA HOLDINGS CO., LTD.	+18.26%	22.46B
SANDOZ GROUP AG	+18.55%	15.04B
CIPLA LIMITED	+18.94%	13.98B
ZYDUS LIFESCIENCES LIMITED	+56.80%	13.15B
ONO PHARMACEUTICAL CO., LTD.	-9.52%	6.89B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.66%	5.71B
RICHTER GEDEON VEGYÉSZETI GYÁR NYILVÁNOSAN MUKÖDO RT.	+4.00%	4.69B

Generic Pharmaceuticals